A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy

Woo Young Kim, Dong Jo Chang, Bryan Hennessy, Hae Jin Kang, Jakyung Yoo, Seung Ho Han, Yoo Shin Kim, Hyun Ju Park, Seung Yong Geo, Gordon Mills, Kyu Won Kim, Waun Ki Hong, Young Ger Suh, Ho Young Lee

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

The natural compound deguelin has promising preventive and therapeutic activity against diverse cancers by directly binding to heat shock protein-90 and thus suppressing its function. Potential side effects of deguelin over a certain dose, however, could be a substantial obstacle to its clinical use. To develop a derivative(s) of deguelin with reduced potential side effects, we synthesized five deguelin analogues (SH-02, SH-03, SH-09, SH-14, and SH-15) and compared them with the parent compound and each other for structural and biochemical features; solubility; and antiproliferative effects on normal, premalignant, and malignant human bronchial epithelial (HBE) and non-small-cell lung cancer (NSCLC) cell lines. Four derivatives destabilized hypoxia-inducible factor-1α as potently as did deguelin. Reversephase protein array (RPPA) analysis in H460 NSCLC cells revealed that deguelin and the derivatives suppressed expression of a number of proteins including heat shock protein- 90 clients and proteins involved in the phosphoinositide 3-kinase/Akt pathway. One derivative, SH-14, showed several features of potential superiority for clinical use: the highest apoptotic activity; no detectable influence on Src/signal transducer and activator of transcription signaling, which can promote cancer progression and is closely related to pathogenesis of Parkinson's disease (deguelin, SH-02 and SH-03 strongly activated this signaling); better aqueous solubility; and less cytotoxicity to immortalized HBE cells (versus deguelin) at a dose (1 μmol/L) that induced apoptotic activity in most premalignant and malignant HBE and NSCLC cell lines. These collective results suggest that the novel derivative SH-14 has strong potential for cancer chemoprevention and therapy, with equivalent efficacy and lesser toxicity (versus deguelin).

Original languageEnglish (US)
Pages (from-to)577-587
Number of pages11
JournalCancer Prevention Research
Volume1
Issue number7
DOIs
StatePublished - Dec 2008
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy'. Together they form a unique fingerprint.

Cite this